-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Fibrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Fibrosarcoma Drug Details: LB-100 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Synovial Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Synovial Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Synovial Sarcoma Drug Details: LB-100 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LB-100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-978 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-978 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-978 in B-Cell Non-Hodgkin Lymphoma Drug Details: CLN-978 is under development...
-
Product Insights
NewMyxoid Liposarcoma – Drugs In Development, 2024
Empower your strategies with our Myxoid Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid/round cell liposarcoma, or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS usually grows in the arms and legs. These tumors grow slowly, and they can spread to other parts of the...
-
Product Insights
NewPleomorphic Liposarcoma – Drugs In Development, 2024
Empower your strategies with our Pleomorphic Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Pleomorphic liposarcoma is a rare and aggressive subtype of liposarcoma, a malignant tumor that arises from fat cells. Unlike other liposarcomas, pleomorphic liposarcoma is characterized by its pleomorphic, or varied and irregular, appearance under the microscope. This subtype often occurs in the deep soft tissues of the limbs and the retroperitoneum. Pleomorphic liposarcoma tends to be more challenging to treat than other...
-
Product Insights
NewLeiomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
NewSynovial Sarcoma – Drugs In Development, 2024
Empower your strategies with our Synovial Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy. The Synovial Sarcoma drugs in development market research report provide...
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...